XML 52 R37.htm IDEA: XBRL DOCUMENT
v3.26.1

Restructuring, Impairment, and Related Charges, Net (Tables) | 12 Months Ended
--- | ---
Mar. 31, 2026
Restructuring and Related Activities [Abstract] |
Schedule of Details for Charges Recorded | Restructuring, impairment, and related charges, net for the year ended March 31, 2026 consisted of the following:
| Year Ended March 31, 2026
(In millions) | North American Pharmaceutical (1) |  |  |  | Prescription Technology Solutions (2) |  | Medical-Surgical Solutions (3) |  | Corporate & Other (4) |  | Total
Severance and employee-related costs, net | $ | 9 |  |  |  |  | $ | 3 |  |  | $ | 14 |  |  | $ | (1) |  |  | $ | 25 |
Exit and other-related costs (5) | 3 |  |  |  |  | — |  |  | 37 |  |  | 151 |  |  | 191 |
Asset impairments and accelerated depreciation | 12 |  |  |  |  | 17 |  |  | (8) |  |  | 8 |  |  | 29 |
Total | $ | 24 |  |  |  |  | $ | 20 |  |  | $ | 43 |  |  | $ | 158 |  |  | $ | 245 |
(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s North American Pharmaceutical segment. (2)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s Prescription Technology Solutions segment. (3)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s Medical-Surgical Solutions segment. (4)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s Corporate and other activities. (5)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. Fiscal 2025 Restructuring, impairment, and related charges, net for the year ended March 31, 2025 consisted of the following:
| Year Ended March 31, 2025
(In millions) | North American Pharmaceutical (1) |  | Oncology & Multispecialty |  | Prescription Technology Solutions |  | Medical-Surgical Solutions (2) |  | Corporate & Other (3) |  | Total
Severance and employee-related costs, net | $ | (3) |  |  | $ | 1 |  |  | $ | — |  |  | $ | 137 |  |  | $ | 3 |  |  | $ | 138 |
Exit and other-related costs (4) | 3 |  |  | — |  |  | 3 |  |  | 53 |  |  | 49 |  |  | 108 |
Asset impairments and accelerated depreciation | 59 |  |  | — |  |  | 9 |  |  | 14 |  |  | 16 |  |  | 98 |
Total | $ | 59 |  |  | $ | 1 |  |  | $ | 12 |  |  | $ | 204 |  |  | $ | 68 |  |  | $ | 344 |
(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s North American Pharmaceutical segment, including an inventory impairment charge of $58 million within "Cost of sales" in the Consolidated Statement of Operations. (2)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s Medical-Surgical Solutions segment. (3)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s Corporate and other activities. (4)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. Fiscal 2024 Restructuring, impairment, and related charges, net for the year ended March 31, 2024 consisted of the following:
| Year Ended March 31, 2024
(In millions) | North American Pharmaceutical (1) |  | Oncology & Multispecialty(1) |  | Prescription Technology Solutions |  | Medical-Surgical Solutions |  | Corporate & Other (1)(2) |  | Total
Severance and employee-related costs, net | $ | 7 |  |  | $ | 5 |  |  | $ | — |  |  | $ | (1) |  |  | $ | (1) |  |  | $ | 10 |
Exit and other-related costs (3) | 3 |  |  | 1 |  |  | 11 |  |  | 12 |  |  | 35 |  |  | 62 |
Asset impairments and accelerated depreciation | 10 |  |  | 3 |  |  | — |  |  | — |  |  | 30 |  |  | 43 |
Total | $ | 20 |  |  | $ | 9 |  |  | $ | 11 |  |  | $ | 11 |  |  | $ | 64 |  |  | $ | 115 |
(1)Includes costs related to operational efficiencies and cost optimization efforts to support the Company’s North American Pharmaceutical, Oncology & Multispecialty, Corporate and other activities. (2)Corporate & other includes costs for business transformation and optimization efforts related to the Company’s technology organization and costs related to the Company’s divested European operations. (3)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.
Schedule of Restructuring Reserve by Type of Cost | The following table summarizes the activity related to the liabilities associated with the Company’s restructuring initiatives for the years ended March 31, 2026 and 2025:
(In millions) | North American Pharmaceutical |  | Oncology & Multispecialty |  | Prescription Technology Solutions |  | Medical-Surgical Solutions |  | Corporate & Other |  | Total
Balance, March 31, 2024 (1) | $ | 23 |  |  | $ | 3 |  |  | $ | 5 |  |  | $ | 1 |  |  | $ | 23 |  |  | $ | 55 |
Restructuring, impairment, and related charges, net | 59 |  | 1 |  |  | 12 |  |  | 204 |  |  | 68 |  |  | 344
Non-cash charges | (58) |  |  | (1) |  |  | (9) |  |  | (14) |  |  | (16) |  |  | (98) |
Cash payments | (8) |  |  | (2) |  |  | (4) |  |  | (99) |  |  | (51) |  |  | (164) |
Other (2) | (5) |  |  | (1) |  |  | (3) |  |  | (2) |  |  | — |  |  | (11) |
Balance, March 31, 2025 (3) | 11 |  |  | — |  |  | 1 |  |  | 90 |  |  | 24 |  |  | 126 |
Restructuring, impairment, and related charges, net | 24 |  |  | — |  |  | 20 |  |  | 43 |  |  | 158 |  |  | 245 |
Non-cash charges | (12) |  |  | — |  |  | (17) |  |  | 8 |  |  | (8) |  |  | (29) |
Cash payments | (4) |  |  | — |  |  | (1) |  |  | (133) |  |  | (161) |  |  | (299) |
Other (2) | (1) |  |  | — |  |  | — |  |  | 2 |  |  | — |  |  | 1 |
Balance, March 31, 2026 (4) | $ | 18 |  |  | $ | — |  |  | $ | 3 |  |  | $ | 10 |  |  | $ | 13 |  |  | $ | 44 |
(1) As of March 31, 2024, the total reserve balance was $55 million, of which $24 million was recorded in “Other accrued liabilities” and $31 million was recorded in “Other non-current liabilities” in the Company’s Consolidated Balance Sheet. (2) Other primarily includes cumulative translation adjustments as well as adjustments to Canadian retail disposal group reserves within North American Pharmaceutical segment in fiscal 2025, and transfers to certain other liabilities for the remaining segments. (3) As of March 31, 2025, the total reserve balance was $126 million, of which $103 million was recorded in “Other accrued liabilities” and $23 million was recorded in “Other non-current liabilities” in the Company’s Consolidated Balance Sheet. (4) As of March 31, 2026, the total reserve balance was $44 million, of which $30 million was recorded in “Other accrued liabilities” and $14 million was recorded in “Other non-current liabilities” in the Company’s Consolidated Balance Sheet.

X
- References No definition available. + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details
Name: | us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details
Name: | us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration